Polymeric Microvalve for Intraocular Pressure Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glaucoma implants face challenges such as inadequate size, material biocompatibility, unpredictable intraocular pressure regulation, fibrosis, and obstruction due to hydrophobic materials, leading to malfunctioning and complications like hypotony and high resistance to flow.
Innovation Solution
A microapparatus with a MEMS-based microvalve system using biocompatible polymeric materials and low-voltage actuating means, incorporating a pressure sensor and actuator diaphragm for active pressure control, designed to minimize size, fibrosis, and power consumption, with a telemetric system for remote adjustment and monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If passive valves with permanent magnets and electromagnetic actuation are used, then intraocular pressure can be regulated, but the implant size becomes too large (above 1 cm) causing fibrosis and tissue reaction
Solution Approach 1:
The patent replaces the electromagnetic actuation system with a purely mechanical pressure-regulating mechanism. The microvalve uses a deformable membrane that responds directly to intraocular pressure changes, eliminating the need for permanent magnets, electromagnetic coils, and power sources that would increase implant size. This mechanical substitution enables pressure regulation while maintaining a compact implant form factor below 1 cm.
Solution Approach 2:
The patent employs a deformable polymer membrane as the core pressure-regulating element. This thin, flexible film can elastically deform in response to pressure changes, opening or closing the drainage aperture as needed. The use of this flexible membrane structure achieves effective pressure control without requiring bulky mechanical components, thereby resolving the contradiction between regulatory reliability and small implant size.
2Ease of manufacture
If silicone materials are used for the implant, then the implant can be manufactured, but hydrophobicity causes obstruction by particles (proteins or cells)
Solution Approach 1:
The patent changes the surface energy parameter of the implant materials by selecting hydrophilic polymers instead of hydrophobic silicone. This parameter change in surface wettability prevents protein and cell adhesion, thereby eliminating particle obstruction while maintaining ease of manufacture through standard polymer processing techniques.
Solution Approach 2:
The patent uses composite polymeric structures combining hydrophilic materials with appropriate mechanical properties. These composite materials provide both the desired hydrophilic surface characteristics to prevent obstruction and the structural integrity needed for implant manufacturing, resolving the contradiction between manufacturability and resistance to particle accumulation.
3Device complexity
If passive valves are used, then the implant structure is simple, but intraocular pressure variations during the day cannot be compensated
Solution Approach 1:
The patent transforms the static passive valve into a dynamic pressure-responsive system. The deformable membrane continuously adapts its opening degree in response to real-time intraocular pressure variations, automatically compensating for diurnal pressure changes without requiring complex control mechanisms. This dynamic response achieves adaptability while maintaining relatively simple device structure.
Solution Approach 2:
The patent implements a self-regulating pressure control system where the deformable membrane automatically responds to pressure changes without external control. The valve opens when pressure exceeds the threshold and closes when pressure drops, providing autonomous pressure compensation that eliminates the need for complex actuation systems while maintaining adaptability to pressure variations.
4Extent of automation
If electrochemical or electromagnetic microvalves are used, then active pressure control is achieved, but power consumption increases and biocompatibility problems occur
Solution Approach 1:
The patent implements a self-powered pressure control system where the deformable membrane uses the intraocular pressure differential itself as the actuating force. No external power source is needed—the pressure gradient that needs to be controlled automatically drives the membrane deformation and valve operation, achieving active pressure control with zero power consumption.
Solution Approach 2:
The patent replaces electromagnetic and electrochemical actuation systems with a pure mechanical pressure-responsive mechanism. By substituting active electronic control with passive mechanical response, the system achieves automated pressure regulation without requiring power input, thereby resolving the contradiction between automation extent and energy consumption.
5Reliability
If passive valves with permanent magnets are used, then pressure regulation is achieved, but fibrosis occurs due to inadequate material biocompatibility
Solution Approach 1:
The patent employs biocompatible polymeric composite materials that combine pressure-regulating functionality with anti-fibrotic properties. These specialized polymers are designed to be inert to surrounding tissues, preventing the inflammatory response and fibrosis that occur with traditional materials containing permanent magnets and electromagnetic components, while maintaining effective pressure control.
Solution Approach 2:
The patent eliminates permanent magnets and electromagnetic components that cause tissue reaction and fibrosis, replacing them with biocompatible polymeric structures. This substitution removes the harmful materials while preserving the pressure regulation function through purely mechanical means, thereby resolving the contradiction between regulatory reliability and biocompatibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves precise and reliable intraocular pressure regulation, reduces fibrosis and obstruction, and ensures long-term biocompatibility, while minimizing power consumption and allowing for telemetric follow-up and adjustment, thereby addressing the limitations of existing implants.
Implementation Method 1
a sensor also comprising a membrane made of a polymeric material which combines these same properties. The sensor and actuator-valve elements are connected to a drainage conduit, the first to deform by the pressure of the ocular globe
Implementation Method 2
The valve design is such that, in case of failure and absence of electrical voltage, its status is normally closed, as the diaphragm closes the valve to the non-operative status
Data Source
AI summary
A microapparatus (11) implantable in the eye (13) includes a cuasi-bistable microvalve (21) commanded by an intraocular pressure sensor (23) in situ. The microvalve mechanism includes a diaphragm (27) made of a conjugated polymer (29) that shows high deformation and biocompatibility capabilities and which volume depends from the electric potential applied by its pair of electrodes (31). The sensor and actuator-valve are coupled to a drainage conduit (15), the first to deform by the pressure in the ocular globe and the second in a position of buckling to normally close the drainage conduit. The sensor has a membrane of conductive polymeric material with these same properties and whose ohmic resistance varies with the mechanical deformation produced by the ocular pressure.